Stenosis of Arteria-Venous Fistula in Maintenance Hemodialysis Patients: Early Intervention Trial

Overview

The purpose of this study is to compare the effect of DSA guided percutaneous balloon dilatation, ultrasound guided percutaneous balloon dilatation and surgical repair in the treatment of Stenosis of Arteria-Venous Fistula in Maintenance Hemodialysis Patients.

Full Title of Study: “Randomized Controlled Trial to Compare Therapeutic Effect of Digital Subtraction Angiography(DSA),Ultrasound Guided Balloon Dilatation and Surgical Reconstruction in Arteria-venous Fistula(AVF) Stenosis in Maintenance Hemodialysis Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2017

Detailed Description

Eligibility Criteria: 1. Patients with long-term maintenance hemodialysis with AVF as the vascular access; 2. Positive clinical examination signs of AVF stenosis (not all required) : (1) the visual examination: edema, prolonged bleeding time, hematoma, aneurysm or constriction of the fistula .(2) the palpation examination: a narrowing of the outflow vein or aneurysm formation. (3) the auscultation examination: high pitch and/or discontinuous murmur. 3. Doppler ultrasound /DSA/magnetic resonance angiography show the diameter of AVF fistula is >50% narrow than the adjacent segment of the fistula lumen. 4. Blood flow of the AVF is <500ml/min or monthly declines of the blood flow>25%. 5. Patient signed the informed consent.

Interventions

  • Device: DSA guided percutaneous balloon dilatation
    • Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
  • Device: Ultrasound guided percutaneous balloon dilatation
    • Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
  • Procedure: Surgical reconstruction
    • Direct surgery to reconstruction the AVF lumen.

Arms, Groups and Cohorts

  • Experimental: Group 1
    • DSA guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
  • Experimental: Group 2
    • Ultrasound guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
  • Experimental: Group 3
    • Surgical reconstruction of the stenosis to reconstruction the lumen of arteriovenous fistula

Clinical Trial Outcome Measures

Primary Measures

  • the patency rate of the AVF after intervention
    • Time Frame: 24 month
    • the patency rate including the primary and the secondary patency rate

Secondary Measures

  • The success rate of AVF stenosis interventions
    • Time Frame: 24 month
    • Described as %.
  • The recurrence rate of AVF stenosis interventions
    • Time Frame: 24 month
    • Described as %.
  • The side effects of AVF stenosis interventions
    • Time Frame: 24 month
    • Described as %.Side effects including bleeding, infection, thrombosis, artery steal syndrome, heart failure, inadequate dialysis, etc.
  • The cost-effectiveness analysis of AVF stenosis interventions
    • Time Frame: 24 month
    • Described as $.

Participating in This Clinical Trial

Inclusion Criteria

1. Patients with long-term maintenance hemodialysis with AVF as the vascular access; 2. Positive clinical examination signs of AVF stenosis (not all required) : (1) the visual examination: edema, prolonged bleeding time, hematoma, aneurysm or constriction of the fistula .(2) the palpation examination: a narrowing of the outflow vein or aneurysm formation. (3) the auscultation examination: high pitch and/or discontinuous murmur; 3. Doppler ultrasound /DSA/MRA show the diameter of AVF fistula is >50% narrow than the adjacent segment of the fistula lumen; 4. Blood flow of the AVF is <500ml/min or monthly declines of the blood flow>25%; 5. Patient signed the informed consent. Exclusion Criteria:

1. allergic to the iodine contrast or gadolinium contrast agent; 2. local infection; 3. the presence of severe coagulation dysfunction (or long-term history of taking warfarin or ticlopidine); 4. the presence of severe artery steal syndrome; 5. stenosis of immature fistula or fistula <2 month after vascular anastomosis; 6. severe central venous stenosis; 7. discontinue hemodialysis treatment (such as to transfer to peritoneal dialysis or kidney transplant); 8. severe cardiac dysfunction (New York Heart Association cardiac functional classification III or worse), unstable angina pectoris, myocardial infarction, severe left ventricular hypertrophy, or severe vascular embolic disease; 9. participated in other clinical trials within 12 weeks; 10. alcohol and/or drug abusers, mental disorders; 11. patients not suitable as the subjects of this trial under the consideration of researchers.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shanghai Changzheng Hospital
  • Collaborator
    • First Affiliated Hospital of Zhejiang University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Changlin Mei, Professor, Director, Division of Nephrology – Shanghai Changzheng Hospital
  • Overall Official(s)
    • Changlin Mei, MD, Principal Investigator, Shanghai Changzheng Hospital
  • Overall Contact(s)
    • Changlin Mei, MD, 0086 21 81885411, chlmei1954@126.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.